Cellectis S.A. (NASDAQ:CLLS) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Cellectis S.A. (NASDAQ:CLLS - Get Free Report) have received an average recommendation of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $6.75.

Several research analysts recently issued reports on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cellectis in a research report on Monday, April 20th. Jefferies Financial Group started coverage on Cellectis in a research note on Tuesday, February 17th. They issued a "buy" rating and a $7.00 target price for the company. Finally, Citizens Jmp restated a "market outperform" rating and issued a $8.00 target price on shares of Cellectis in a research note on Tuesday, April 14th.

Cellectis Stock Up 1.3%

Shares of CLLS opened at $3.95 on Friday. Cellectis has a 52 week low of $1.33 and a 52 week high of $5.48. The stock has a market capitalization of $396.34 million, a price-to-earnings ratio of -5.90 and a beta of 2.94. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.62 and a current ratio of 1.62. The stock has a fifty day moving average of $3.69 and a 200-day moving average of $4.01.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings results on Thursday, March 19th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.16). The firm had revenue of $15.50 million during the quarter, compared to the consensus estimate of $10.74 million. Cellectis had a negative net margin of 84.92% and a negative return on equity of 69.38%.

Hedge Funds Weigh In On Cellectis

A number of hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP boosted its stake in Cellectis by 1,610.3% during the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company's stock valued at $864,000 after purchasing an additional 168,038 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Cellectis in the 4th quarter worth approximately $15,385,000. Global Retirement Partners LLC bought a new stake in shares of Cellectis in the 4th quarter worth approximately $34,000. Millennium Management LLC raised its holdings in shares of Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company's stock worth $165,000 after purchasing an additional 22,080 shares during the period. Finally, Citadel Advisors LLC bought a new stake in shares of Cellectis in the 3rd quarter worth approximately $633,000. Institutional investors and hedge funds own 63.90% of the company's stock.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company's core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.